title: Quetiapine prevents oligodendrocyte and myelin loss and promotes maturation of oligodendrocyte progenitors in the hippocampus of global cerebral ischemia mice.
abstract: White matter impairment is a feature of vascular depression. The anti-psychotic quetiapine has been shown to enhance the therapeutic effects of anti-depressants on vascular depression, but the mechanism remains unknown. In this study, we found that 2 weeks of treatment with quetiapine prior to bilateral carotid artery occlusion and reperfusion, in an animal model of vascular depression, resulted in reduced myelin breakdown and oligodendrocyte loss compared to placebo-treated mice on post-operative day (POD) 7. For late stage of recovery (POD40), quetiapine treatment resulted in enhanced oligodendrocyte maturation relative to placebo. The results suggest that quetiapine is a potential intervention for oligodendrocyte damage and this may contribute to its anti-depressant effects through white matter protection in vascular depression.
authors: Department of Neurology, Shanghai Changhai Hospital, Secondary Military Medical University, Shanghai, PR China.
authors: Xiaoying
authors: X
authors: Bi
authors: Yanbo
authors: Y
authors: Zhang
authors: Bin
authors: B
authors: Yan
authors: Shaokuan
authors: S
authors: Fang
authors: Jue
authors: J
authors: He
authors: Dai
authors: D
authors: Zhang
authors: Zhijun
authors: Z
authors: Zhang
authors: Jiming
authors: J
authors: Kong
authors: Qingrong
authors: Q
authors: Tan
authors: Xin-Min
authors: XM
authors: Li
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000941:Antigens / Q000378:metabolism; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D002545:Brain Ischemia / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D001973:Bromodeoxyuridine / Q000378:metabolism; D002340:Carotid Artery Diseases / Q000150:complications; D002454:Cell Differentiation / Q000187:drug effects; D003987:Dibenzothiazepines / Q000008:administration & dosage*; D004195:Disease Models, Animal; D005786:Gene Expression Regulation / Q000187:drug effects; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D006624:Hippocampus / Q000187:drug effects / Q000473:pathology*; D008297:Male; D051379:Mice; D004676:Myelin Basic Protein / Q000378:metabolism; D009186:Myelin Sheath / Q000378:metabolism*; D009836:Oligodendroglia / Q000187:drug effects*; D011509:Proteoglycans / Q000378:metabolism; D000069348:Quetiapine Fumarate; D013997:Time Factors; D000099216:Chondroitin Sulfate Proteoglycan 4
chemical_list: D000941:Antigens; D014150:Antipsychotic Agents; D001973:Bromodeoxyuridine; D003987:Dibenzothiazepines; D005904:Glial Fibrillary Acidic Protein; D004676:Myelin Basic Protein; D011509:Proteoglycans; D000069348:Quetiapine Fumarate; D000099216:Chondroitin Sulfate Proteoglycan 4